person · Reporting owner
Chambers Michael Andrew
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | June 04, 2026 | June 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date June 04, 2026 · Filed June 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,535 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 27,535 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. |
| Common StockSEC Table I · non-derivative | IndirectBy Revocable Trust | 476,492 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 476,492 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 6, 2026 00:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 16,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-260246 · ownership.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,535 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantConvertible Senior Notes · Derivative | Not disclosed | Not disclosed Strike: $60.00 | $20,000,000.00 |
DisclosureSEC source: 0001193125-25-326980 · ownership.xml · derivative · entry 2 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 333,333 shares Expires not disclosed F1 · date: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025. F1 · price: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025. F3 · derivative.exercise_date: The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. F3 · derivative.expiration_date: The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. F3 · derivative.underlying_shares: The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Disposition to issuerConvertible Senior Notes · Derivative | Not disclosed | Not disclosed Strike: $141.97 | $20,000,000.00 |
DisclosureSEC source: 0001193125-25-326980 · ownership.xml · derivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 140,875 shares Expires not disclosed F1 · date: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025. F1 · price: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025. F2 · derivative.exercise_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. F2 · derivative.expiration_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. F2 · derivative.underlying_shares: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 4,792 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037531 · ownership.xml · derivative · entry 3 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,792 Underlying: Common Stock · 4,792 shares Expires 2035-03-10 Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037531 · ownership.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,660 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 5,648 | $134.66 | $760,559.68 |
DisclosureSEC source: 0000950170-24-098859 · ownership.xml · nonDerivative · entry 3 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 284,034 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $134.48 to $134.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 18,284 | $134.06 | $2,451,153.04 |
DisclosureSEC source: 0000950170-24-098859 · ownership.xml · nonDerivative · entry 2 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 278,386 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.47 to $134.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 13,106 | $133.07 | $1,744,015.42 |
DisclosureSEC source: 0000950170-24-098859 · ownership.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 260,102 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $132.46 to $133.46, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,679 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026613 · ownership.xml · derivative · entry 3 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,679 Underlying: Common Stock · 3,679 shares Expires 2034-03-01 Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026613 · ownership.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,277 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 4,032 | $109.89 | $443,076.48 |
DisclosureSEC source: 0001209191-23-045766 · doc4.xml · nonDerivative · entry 2 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 246,996 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $109.67 to $110, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 5,947 | $109.19 | $649,352.93 |
DisclosureSEC source: 0001209191-23-045766 · doc4.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 242,964 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 23,686 | $108.05 | $2,559,272.30 |
DisclosureSEC source: 0001209191-23-045498 · doc4.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 237,017 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.70 to $108.48, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 11:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 31,570 | $106.26 | $3,354,628.20 |
DisclosureSEC source: 0001209191-23-045366 · doc4.xml · nonDerivative · entry 3 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 213,331 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.01 to $106.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 11:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 1,091 | $105.90 | $115,536.90 |
DisclosureSEC source: 0001209191-23-045366 · doc4.xml · nonDerivative · entry 2 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 181,761 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105 to $106, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 11:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 2,206 | $104.67 | $230,902.02 |
DisclosureSEC source: 0001209191-23-045366 · doc4.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 180,670 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.99 to $104.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,257 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017406 · doc4.xml · derivative · entry 3 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,257 Underlying: Common Stock · 3,257 shares Expires 2033-03-06 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017406 · doc4.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,431 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 6, 2024. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 6,250 | $105.16 | $657,250.00 |
DisclosureSEC source: 0001209191-22-050002 · doc4.xml · nonDerivative · entry 3 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,178 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.085 to $105.40, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 30,106 | $104.67 | $3,151,195.02 |
DisclosureSEC source: 0001209191-22-050002 · doc4.xml · nonDerivative · entry 2 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,928 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $104.065 to $105.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 20,744 | $103.87 | $2,154,679.28 |
DisclosureSEC source: 0001209191-22-050002 · doc4.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,822 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.06 to $104.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 12:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantConvertible Senior Notes · Derivative | Not disclosed | $20,000,000.00 Strike: $141.97 | $20,000,000.00 |
DisclosureSEC source: 0001209191-22-049820 · doc4.xml · derivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Revocable Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 140,879 shares Expires not disclosed F1 · date: On September 13, 2022, the Reporting Person and the Company entered into a purchase agreement related to a purchase by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") in a private placement from the Company. The private placement is expected to close on September 16, 2022, subject to customary closing conditions. F1 · kind: On September 13, 2022, the Reporting Person and the Company entered into a purchase agreement related to a purchase by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") in a private placement from the Company. The private placement is expected to close on September 16, 2022, subject to customary closing conditions. F2 · derivative.exercise_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. F2 · derivative.expiration_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. F2 · derivative.underlying_shares: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 12:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 6,060 | $108.80 | $659,328.00 |
DisclosureSEC source: 0001209191-22-046973 · doc4.xml · nonDerivative · entry 2 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,078 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.57 to $109.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 12:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 40,110 | $108.20 | $4,339,902.00 |
DisclosureSEC source: 0001209191-22-046973 · doc4.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,018 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.56 to $108.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:22 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 8,329 | $0.00 Strike: $72.58 | $0.00 |
DisclosureSEC source: 0001209191-22-034739 · doc4.xml · derivative · entry 3 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,329 Underlying: Common Stock · 8,329 shares Expires 2032-06-02 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning June 2, 2023. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:22 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 4,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034739 · doc4.xml · nonDerivative · entry 1 Chambers Michael Andrew · CIK 0001932527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,908 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning June 2, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.